دورية أكاديمية
أعرض في EDS

A Prospective Correlation of Tissue Histopathology With Nucleic Acid Yield in Metastatic Castration-Resistant Prostate Cancer Biopsy Specimens.

التفاصيل البيبلوغرافية
العنوان: A Prospective Correlation of Tissue Histopathology With Nucleic Acid Yield in Metastatic Castration-Resistant Prostate Cancer Biopsy Specimens.
المؤلفون: Jimenez RE; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN., Atwell TD; Department of Radiology, Mayo Clinic, Rochester, MN., Sicotte H; Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN., Eckloff B; Medical Genome Facility, Mayo Clinic, Rochester, MN., Wang L; Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN., Barman P; Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN., Sinnwell JP; Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN., Eiken PW; Department of Radiology, Mayo Clinic, Rochester, MN., McMenomy BP; Department of Radiology, Mayo Clinic, Rochester, MN., Tan W; Department of Hematology/Oncology, Mayo Clinic, Jacksonville, FL., Wang L; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN., Carlson RE; Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN., Kohli M; Department of Medical Oncology, Mayo Clinic, Rochester, MN.
المصدر: Mayo Clinic proceedings. Innovations, quality & outcomes [Mayo Clin Proc Innov Qual Outcomes] 2019 Feb 26; Vol. 3 (1), pp. 14-22. Date of Electronic Publication: 2019 Feb 26 (Print Publication: 2019).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Inc Country of Publication: Netherlands NLM ID: 101728275 Publication Model: eCollection Cited Medium: Internet ISSN: 2542-4548 (Electronic) Linking ISSN: 25424548 NLM ISO Abbreviation: Mayo Clin Proc Innov Qual Outcomes Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Netherlands] : Elsevier Inc., [2017]-
مستخلص: Objective: To determine histopathologic, exome, and transcriptome nucleic acid material yield from prospectively collected metastatic tissue biopsy specimens in patients with metastatic castration-resistant prostate cancer (mCRPC).
Patients and Methods: Patients with mCRPC initiating abiraterone acetate therapy underwent 2 serial metastatic site core needle biopsies after study activation on May 17, 2013. Multiple cores were obtained, and from each core, 1- to 2-mm segments were separated and formalin fixed for histopathologic examination. Tumor purity was determined for DNA and RNA from the rest of the biopsy specimen. RNA quality was assessed by calculation of an RNA integrity number and a DV200 score.
Results: A total of 89 patients underwent 172 uniformly processed core needle biopsies (89 on visit 1 and 83 on visit 2) between May 30, 2013, and September 10, 2015. Metastatic sites biopsied included bone (131), lymph nodes (31), liver (5), lung (3), and pelvic soft tissues (2). Of the 172 biopsy specimens, 85 (49%) had at least one of the multiple cores positive for tumor on histopathologic examination (53 of 88 [60%] from visit 1 and 32 of 83 [39%] from visit 2; P =.006). Metastatic carcinoma was observed in 50 of 130 bone lesion specimens (38%), compared to 35 of 41 nonbone specimens (85%) ( P <.001). More than 10% tumoral DNA purity was observed in 89% and 80% of visit 1 and visit 2 biopsy specimens, respectively. Similarly, more than 10% tumor RNA purity was observed in 79% of visit 1 vs 59% for visit 2 ( P =.008). In all, 134 of 172 procedures (78%) yielded tumor material either by histopathologic or nucleic acid purity analysis.
Conclusion: This study found that biopsy specimens from mCRPC sites yield adequate histopathologic, exome, and transcriptome material in most, but not all, cases. This finding has relevance for future genome sequencing studies on the introduction of targeted therapeutic agents.
Trial Registration: clinicaltrials.gov Identifier: 01953640.
References: Clin Cancer Res. 2000 Mar;6(3):1038-45. (PMID: 10741732)
Cancer Cell. 2010 Jul 13;18(1):11-22. (PMID: 20579941)
Clin Cancer Res. 2011 Jun 15;17(12):3924-32. (PMID: 21555375)
Nature. 2012 Jul 12;487(7406):239-43. (PMID: 22722839)
Clin Exp Metastasis. 2014 Feb;31(2):159-67. (PMID: 24085599)
J Clin Invest. 2013 Nov;123(11):4918-22. (PMID: 24135135)
Prostate Cancer Prostatic Dis. 2014 Mar;17(1):23-7. (PMID: 24366412)
Nat Med. 2014 Jun;20(6):682-8. (PMID: 24836576)
Bioinformatics. 2014 Sep 15;30(18):2678-80. (PMID: 24876377)
Eur Urol. 2015 Jan;67(1):53-60. (PMID: 24882673)
Prostate Cancer Prostatic Dis. 2014 Dec;17(4):325-31. (PMID: 25091040)
Cell. 2015 May 21;161(5):1215-1228. (PMID: 26000489)
JAMA Oncol. 2015 Jul;1(4):466-74. (PMID: 26181256)
N Engl J Med. 2015 Oct 29;373(18):1697-708. (PMID: 26510020)
Oncotarget. 2015 Dec 29;6(42):44781-93. (PMID: 26575023)
PLoS One. 2015 Dec 22;10(12):e0145176. (PMID: 26695660)
Oncotarget. 2016 Feb 23;7(8):8839-49. (PMID: 26814433)
Curr Opin Urol. 2016 May;26(3):231-9. (PMID: 26909474)
BJU Int. 2017 Nov;120(5B):E30-E44. (PMID: 27539393)
Int J Mol Sci. 2016 Sep 20;17(9):null. (PMID: 27657044)
Dis Markers. 2016;2016:3825819. (PMID: 27766004)
Ann Oncol. 2018 Feb 1;29(2):352-360. (PMID: 29069303)
Cancer. 2018 Mar 1;124(5):1008-1015. (PMID: 29266381)
CA Cancer J Clin. 2018 Jan;68(1):7-30. (PMID: 29313949)
فهرسة مساهمة: Keywords: CN, copy number; MAF, mutant allele frequency; RIN, RNA integrity number; mCRPC, metastatic castration-resistant prostate cancer
تواريخ الأحداث: Date Created: 20190323 Latest Revision: 20220408
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC6410334
DOI: 10.1016/j.mayocpiqo.2018.12.005
PMID: 30899904
قاعدة البيانات: MEDLINE
الوصف
تدمد:2542-4548
DOI:10.1016/j.mayocpiqo.2018.12.005